Eli Lilly and Co. won a U.S. appeals court ruling that upholds the validity of a patent for the lung-cancer drug Alimta and blocks generic competition through 2017. Alimta generated $2.5 billion in sales last year.
Group sees role in cellular therapy as growth area with profit margins higher than core business.
Erbitux, a cancer treatment made by Indianapolis-based Eli Lilly and Co.'s Imclone unit, failed to help patients with advanced stomach tumors in a late-stage clinical trial.
The university says the gift from an alumnus will fund three new endowed professorships in adult and all forms of non-embryonic stem cell research, in hopes of accelerating discovery of new treatments for heart disease, diabetes and some cancers.
Treatments for central nervous system diseases have a huge potential payoff, analysts say. A hint of whether the gamble may pay off is due in the second half of this year, as Eli Lilly and Co. and Pfizer Inc. announce results for Alzheimer’s drugs that attack the same protein as Roche’s experimental drug.
IBM’s supercomputer Watson is already a “Jeopardy!” champion. Now, three doctors in Indianapolis are trying to teach it how to treat cancer.
Local health care providers won’t find an easy replacement for the grant money supplied by Susan G. Komen for the Cure. That money could be in jeopardy, as grass-roots Komen supporters appear to be sitting out of this year’s Race for the Cure in response to a national controversy over grants to Planned Parenthood.
Endocyte Inc. will submit its ovarian cancer drug EC145 for European market approval in the third quarter of this year after the European Commission granted it orphan drug status.
Little Red Door Cancer Agency strives to make the most of life and the least of cancer.
After spending most of 2011 as a Wall Street darling, the year ended ugly for Endocyte Inc. But CEO Ron Ellis thinks the West Lafayette-based drug developer is in better position than ever.
Dr. Bryan Schneider, a professor at the Indiana University School of Medicine, led a team of researchers in identifying genetic variations that dispose some breast cancer patients to neuropathy when they are receiving chemotherapy with the drug Taxol. Schneider’s research was named one of the biggest advances in cancer research this year by the American Society of Clinical Oncology. The society’s foundation also gave Schneider a three-year, $450,000 grant to further the research.
Carmel resident David Wasilewski has launched WhatNext, a website that uses algorithms to make it easier for cancer patients to connect with others in similar circumstances. Wasilewski, 39, spent eight years as chief operating officer of the Spanx line of body shapers and did health care consulting before that. In addition to helping patients, he thinks WhatNext can become a way for health care organizations share their expertise with patients in need.
If approved for continuation maintenance, Eli Lilly and Co.’s Alimta could be used for longer stretches in lung cancer patients, generating more revenue.
A German researcher disputed the validity of a study that found Byetta and another diabetes drug increase cancer risk.
Dr. Murray Korc, an internationally known pancreatic cancer researcher, comes to the cancer center as the first Myles Brand Professor of Cancer Research. The position is funded through a Lilly Endowment grant.
A billboard near the Indianapolis Motor Speedway features an image of hot dogs poking out of a cigarette pack adorned with a skull and crossbones. A message warns viewers that "hot dogs can wreck your health."
Central Indiana Cancer Centers sold its five facilities to IU Health and transferred its 150 employees to the Indianapolis-based hospital system. The 16 physicians in the practice will remain independent, but they have signed a service agreement with IU Health that pulls the two entities into a tight embrace.
Eli Lilly and Co.'s lung cancer treatment Alimta is poised for continued growth based on recently released study data, according to a new Credit Suisse analyst report.
Eli Lilly and Co.’s patent-infringement claim over Hospira Inc.’s generic version of the cancer treatment Gemzar will be investigated by a U.S. trade agency with the power to block imports of the copycat drug.
New investors got in for $6 a share—which is less than the average price paid by prior investors, a regulatory filing reveals.
